The enrollment and treatment phase of more than 400 patients with knee osteoarthritis have been completed. These patients are part of the Albatross Study which encompasses four countries: Italy, France, Germany, and Spain.
The aim of the Albatross Study (phase II) is to provide primary indications regarding the effectiveness of Fasitibant, an innovative drug for the treatment of intra-articular osteoarthritis, a widespread and debilitating disease especially in the elderly population.
The Fasitibant molecule results from the Menarini Group’s research in pain pathophysiology.
The Group’s research in recent years has led to the citation of 5 of its researchers in the influential ISI chart of the United States which lists research excellence worldwide.

"The first results of the Albatross Study are expected in the second quarter of 2011. In the same period we also are expecting the results of another important study, MIMOSA. This study aims to evaluate the therapeutic effectiveness of Abagovomab, an anti-cancer vaccine for the treatment of ovarian cancer which affects about 200,000 women each year in the world, and more than 60,000 in Europe. For this study, nearly 900 women were enrolled in 151 trial centers in the United States and Europe," stated Dr. Carlo Alberto Maggi, Director of Research of the Menarini Group.